Ibrutinib-Based Treatment Clinical Trial Updates

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia.

We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.

Two dear friends have introduced helpful items to me, such as a chemo jacket since I became cold in the treatment room.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with chronic lymphocytic leukemia, about his diagnosis and treatment journey.

Patients with relapsed or refractory CLL or SLL may benefit from receiving Brukinsa instead of Imbruvica, as Brukinsa demonstrated superior effectiveness.

I’ve recently started on chemotherapy pills instead of infusions and the bitterness reminds me to accept not only the bitterness of the pill, but in life too.